Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

XFOR


Fundamental

Company: X4 Pharmaceuticals Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -10.01
Insider Own: 10.44%
Shs Outstand: 87.44M
Perf Week: -4.21%
Market Cap: 298.17M
Forward P/E: -
EPS next Y: -0.87
Insider Trans: 0.95%
Shs Float: 78.31M
Perf Month: -9.55%
Enterprise Value: 253.11M
PEG: -
EPS next Q: -0.25
Inst Own: 62.51%
Short Float: 3.99%
Perf Quarter: -11.89%
Income: -95.09M
P/S: 8.77
EPS this Y: 64.50%
Inst Trans: 45.54%
Short Ratio: 5.30
Perf Half Y: 8.60%
Sales: 33.98M
P/B: 1.39
EPS next Y Percentage: 57.00%
ROA: -55.66%
Short Interest: 3.12M
Perf YTD: -14.75%
Book/sh: 2.45
P/C: 2.44
EPS next 5Y: 48.40%
ROE: -156.87%
52W High: 16.29 -79.07%
Perf Year: -77.38%
Cash/sh: 1.40
P/FCF: -
EPS past 3/5Y: 63.98% 47.41%
ROIC: -69.02%
52W Low: 1.35 152.59%
Perf 3Y: -87.97%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: 81.58%
Volatility W: 7.04%
Volatility M: 5.65%
Perf 5Y: -98.72%
Dividend TTM: -
EV/Sales: 7.45
EPS Y/Y TTM: -294.29%
Oper. Margin: -291.06%
ATR (14): 0.22
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 5.48
Sales Y/Y TTM: 2925.73%
Profit Margin: -279.86%
RSI (14): 39.70
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 5.65
EPS Q/Q: 87.43%
SMA20: -7.14%
Beta: 0.44
Target Price: 9.33
Payout: -
Debt/Eq: 1.26
Sales Q/Q: 215.18%
SMA50: -10.43%
Rel Volume: 0.27
Prev Close: 3.37
Employees: 143
LT Debt/Eq: 1.24
Earnings: Nov 05 BMO
SMA200: 6.18%
Avg Volume: 589.31K
Price: 3.41
IPO: Nov 16, 2017
Option/Short: No / Yes
EPS/Sales Surpr.: -36.63% -7.22%
Trades:
Volume: 160,815
Change: 1.19%

Technical:


Latest News:

Tractor Supply Company to open in Oxford, bring jobs - Journal-News somewhat bullish
TSCO

Summary: Tractor Supply Company is expanding its presence in Oxford with a new store that could bring up to 30 jobs and attract customers from surrounding areas. The city council and staff are supporting the project by assisting with location planning and traffic studies.

Full article
2024-06-29T12:59:52Z
BlackRock Reduces Stake in Oxford Biomedica - TipRanks.com somewhat bearish
GB:OXB

Summary: BlackRock, Inc. reduces its stake in Oxford BioMedica PLC from over 5% to less than 5% in both direct and indirect voting rights.

Full article
2024-06-21T14:22:46Z
A Travis Scott x Nike Air Jordan 1 Low OG Surfaces in “Dark Pony/Pink Oxford” somewhat bullish
NKE

Summary: Nike Air Jordan 1 will release new collaboration pairs with Travis Scott in 2025 celebrating its 40th anniversary, featuring unique colorways and special packaging. The rumored 'Dark Pony/Pink Oxford' design is expected to have distinctive features like reverse profile Swooshes and Cactus Jack branding.

Full article
2024-05-21T06:10:13Z
Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny - GlobeNewswire neutral
OXM

Summary: Oxford Industries, Inc. will be participating in the 19th Annual Needham Technology, Media, & Consumer Conference in New York.

Full article
2024-05-08T20:25:16Z
Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was to Participate in the 19th ... neutral
OXM

Summary: Oxford Industries, Inc. will be participating in the 19th Annual Needham Technology, Media, & Consumer Conference in New York on May 14, 2024.

Full article
2024-05-08T20:12:56Z
Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was to Participate in ... - Yahoo Finance neutral
OXM

Summary: Oxford Industries, Inc. will be participating in the 19th Annual Needham Technology, Media, & Consumer Conference in New York.

Full article
2024-05-08T20:08:15Z
Nike Air Vapormax 2023 Flyknit Arrives in "Medium Olive/Pink Oxford" - Hypebeast neutral
NKE

Summary: Nike has unveiled the latest colorway of its Nike Air Vapormax 2023 Flyknit sneaker in 'Medium Olive/Pink Oxford', equipped with the latest Max Air technology and sans midsole for a lightweight and versatile feel.

Full article
2024-05-08T16:40:31Z
The IRA, BMS' Big Cuts, First WHIM Approval | BioSpace neutral
JNJ BMY GILD MRK LLY XFOR

Summary: Federal judge in New Jersey dismissed claims from Johnson & Johnson and Bristol Myers Squibb about Medicare's drug price negotiations program, BMS announced layoffs of 2,200 people by 2024, Several pharmaceutical companies reported exceeding Q1 earnings expectations, X4 Pharmaceuticals received approval for its first commercial drug for an ultra-rare disease called WHIM.

Full article
2024-05-01T13:30:34Z